jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Bronchoalveolar Lavage (BAL) by LBC

Cancer
image

Report in 48Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Collection of lung fluid for cytology (Liquid Based Cytology).

₹1,406₹2,009

30% OFF

Bronchoalveolar Lavage (BAL) by LBC - Comprehensive Medical Test Guide

  • Section 1: Why is it done?
    • Test Description: Bronchoalveolar Lavage (BAL) is a diagnostic procedure that involves instilling sterile saline solution into the lungs via bronchoscopy and then suctioning it back to collect cells and fluid from the lower respiratory tract. Liquid-based cytology (LBC) processing provides a standardized method for analyzing these cells to detect infections, malignancies, inflammatory conditions, and other pulmonary pathologies.
    • Primary Indications:
      • Diagnosis of opportunistic infections in immunocompromised patients (PCP, CMV, fungal infections)
      • Evaluation of persistent cough, fever, or abnormal lung infiltrates
      • Detection of malignancy in suspected lung cancer cases
      • Investigation of interstitial lung diseases and inflammatory conditions
      • Assessment of allograft rejection in lung transplant recipients
      • Identification of hemosiderin-laden macrophages in hemorrhage cases
    • Typical Timing/Circumstances: Performed during bronchoscopy when lower respiratory tract sampling is required. Often ordered emergently in hospitalized patients with fever and lung infiltrates, or electively in outpatient settings for diagnostic evaluation.
  • Section 2: Normal Range
    • Normal Cell Differential Counts:
      • Macrophages: 80-90% (predominant cell type)
      • Lymphocytes: 7-15%
      • Neutrophils: 1-5%
      • Eosinophils: 0-2%
      • Epithelial cells: <5%
    • Normal Finding Interpretation: No organisms identified, no malignant cells detected, negative for infection, normal inflammatory cell patterns, absence of hemosiderin-laden macrophages (except in smokers), no evidence of specific pulmonary pathology
    • Units of Measurement: Percentage (%) for differential cell counts, qualitative reporting for organisms and malignancy, total cell count per mL when quantified
    • Normal vs. Abnormal Interpretation:
      • Normal: Cell counts within expected ranges, absence of pathogenic organisms and malignant cells, normal macrophage predominance reflecting alveolar clearance function
      • Abnormal: Elevated neutrophils (bacterial/fungal infection), increased lymphocytes (viral infection, interstitial pneumonitis), eosinophils present (parasitic/allergic), presence of organisms, malignant cells identified, abnormal cell morphology
  • Section 3: Interpretation
    • Cell Differential Pattern Interpretation:
      • Neutrophil-Predominant Pattern (>15%): Suggests bacterial pneumonia, fungal infections, acute respiratory distress syndrome (ARDS), aspiration pneumonia, or acute inflammation. May also indicate recent smoking or cystic fibrosis.
      • Lymphocyte-Predominant Pattern (>25%): Indicates viral infections, hypersensitivity pneumonitis, sarcoidosis, lymphangitic carcinomatosis, or interstitial pneumonitis. CD4/CD8 ratio analysis aids in distinguishing between conditions.
      • Eosinophil-Predominant Pattern (>5%): Associated with eosinophilic pneumonia, parasitic infections, drug reactions, allergic bronchopulmonary aspergillosis (ABPA), or fungal infections.
    • Infectious Organism Detection:
      • Bacteria: Confirms bacterial pneumonia; identification guides antibiotic selection. Gram stain and culture results determine specific pathogens.
      • Fungi: Detection of Pneumocystis jirovecii (PCP), Candida, Aspergillus, Cryptococcus, or Histoplasma indicates opportunistic or community-acquired fungal infections. Critical in immunocompromised patients.
      • Viruses: Cytomegalovirus (CMV), herpes simplex virus (HSV), influenza, or respiratory syncytial virus (RSV) identification via staining or molecular methods guides antiviral therapy.
      • Parasites: Rare finding; indicates parasitic lung infection requiring specific antiparasitic treatment.
    • Malignancy Detection: Presence of malignant cells indicates lung carcinoma, lymphoma, or metastatic disease. Cell morphology, size, chromatin pattern, and atypical features determine malignancy type. Negative BAL does not exclude malignancy; sensitivity ranges from 40-80% depending on tumor location and size.
    • Hemosiderin-Laden Macrophages: Presence indicates pulmonary hemorrhage, diffuse alveolar hemorrhage (DAH), acute or chronic bleeding into alveoli. Increased in smokers and may be normal variant in some contexts.
    • Factors Affecting Results:
      • Location of sampling within lung (different lobes have different cell populations)
      • Recent antibiotic or antifungal therapy may reduce organism recovery
      • Volume of saline instilled and retrieved affects cell yield and concentration
      • Smoking status increases baseline neutrophils and hemosiderin-laden macrophages
      • Immunocompromised status influences infection susceptibility patterns
      • Time delay between collection and processing affects cell viability
  • Section 4: Associated Organs
    • Primary Organ System: Respiratory system, specifically the lower respiratory tract including lungs (alveoli, small airways, and lung parenchyma). Indirectly assesses systemic immune function and overall patient health status.
    • Diseases Associated with Abnormal Results:
      • Infectious Diseases: Pneumocystis jirovecii pneumonia (PCP), bacterial pneumonia, tuberculosis, atypical mycobacterial infections, viral pneumonitis (CMV, HSV, influenza), fungal infections (Aspergillus, Candida, Histoplasma, Cryptococcus), nocardiosis
      • Malignancies: Lung cancer (adenocarcinoma, squamous cell carcinoma, small cell carcinoma), lymphoma involving lung, lymphangitic carcinomatosis, metastatic disease to lungs
      • Inflammatory/Interstitial Lung Diseases: Sarcoidosis, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, non-specific interstitial pneumonia (NSIP), organizing pneumonia, acute respiratory distress syndrome (ARDS)
      • Hemorrhagic Disorders: Diffuse alveolar hemorrhage (DAH), Goodpasture syndrome, vasculitis, anti-GBM disease, thrombocytopenia, anticoagulation complications
      • Transplant-Related Conditions: Acute rejection, chronic rejection (bronchiolitis obliterans), infection in immunosuppressed transplant recipients
      • Other Pulmonary Conditions: Eosinophilic pneumonia, allergic bronchopulmonary aspergillosis (ABPA), cystic fibrosis, bronchiectasis, aspiration pneumonia
    • Complications and Risks Associated with Abnormal Results:
      • Respiratory failure from untreated pneumonia or acute infection
      • Sepsis from bacterial or fungal lung infections in immunocompromised patients
      • Hemodynamic instability from massive pulmonary hemorrhage
      • Rapid disease progression with untreated malignancy
      • Lung transplant rejection if allograft dysfunction not addressed
      • Progressive respiratory compromise from interstitial lung disease
      • Hypoxemia from chronic inflammation or infection
  • Section 5: Follow-up Tests
    • Recommended Tests Based on BAL Findings:
      • If Infection Suspected:
        • BAL Gram stain and bacterial culture with sensitivity testing
        • Fungal stain (KOH, GMS) and fungal culture with speciation
        • Acid-fast stain for mycobacteria and mycobacterial culture
        • Viral testing (DFA, PCR, culture for CMV, HSV, influenza, RSV)
        • Special stains for Pneumocystis jirovecii (IF, GMS, DIF)
        • Blood cultures and serum biomarkers (procalcitonin, CRP)
        • Chest CT or high-resolution CT (HRCT) to assess lung involvement
        • Repeat BAL if initial results inconclusive or clinical suspicion remains high
      • If Malignancy Suspected:
        • Immunocytochemistry (ICC) on BAL specimen for tumor marker identification
        • Flow cytometry for lymphomas and hematolymphoid malignancies
        • Molecular testing (FISH, PCR) if specific malignancy suspected
        • CT chest/abdomen/pelvis for staging and metastasis assessment
        • Transbronchial or percutaneous biopsy for definitive tissue diagnosis
        • PET-CT for tumor metabolic activity and lymph node involvement
        • Tumor markers (serum or BAL) depending on malignancy type
      • If Inflammatory Disease Suspected:
        • CD4/CD8 lymphocyte ratio analysis (high ratio suggests sarcoidosis)
        • Serum and BAL ACE level measurement for sarcoidosis
        • Transbronchial biopsy for tissue diagnosis (granulomas)
        • High-resolution CT (HRCT) of chest for pattern assessment
        • Pulmonary function testing (PFTs) for functional assessment
        • Autoimmune serology (ANA, anti-GBM, ANCA) if vasculitis considered
      • If Hemorrhage Detected:
        • Coagulation studies (PT/INR, aPTT, platelets) for bleeding diathesis
        • Hemoglobin/hematocrit trending for hemorrhage severity assessment
        • Vasculitis serologies (ANCA, anti-GBM, ANA, complement levels)
        • Kidney biopsy if anti-GBM disease suspected (Goodpasture syndrome)
        • Chest imaging to monitor hemorrhage extent and resolution
    • Monitoring Frequency for Ongoing Conditions:
      • Sarcoidosis: Repeat BAL not routine; clinical monitoring and imaging every 3-12 months depending on disease progression
      • Lung Transplant Recipients: Repeat BAL for surveillance of infection and rejection at 6 weeks, 3 months, and annually; or sooner if clinical deterioration
      • Chronic Infections (TB, MAC): Repeat BAL to assess treatment response every 2-3 months during therapy if initially positive
      • Interstitial Lung Disease: Repeat BAL not routine; clinical and functional monitoring every 3-6 months
  • Section 6: Fasting Required?
    • Fasting Requirement: YES - Fasting is required
    • Fasting Duration: Minimum 6-8 hours fasting from food and drink (except water). Typically performed in morning after overnight fasting.
    • Rationale for Fasting: Fasting reduces aspiration risk during bronchoscopy procedure and minimizes gastric contents in stomach, which is critical given the airway manipulation involved.
    • Medications to Continue or Avoid:
      • Hold: Anticoagulants (warfarin, direct oral anticoagulants) typically held 3-5 days prior with cardiology/internal medicine consultation; aspirin and NSAIDs generally held 3-7 days before procedure to reduce bleeding risk
      • Continue: Most cardiac and respiratory medications; take with small sips of water morning of procedure only if approved; insulin or diabetes medications require special management consultation
    • Additional Patient Preparation Requirements:
      • Obtain informed consent after discussion of risks (perforation, bleeding, aspiration, infection) and benefits
      • Pre-procedure laboratory testing: CBC, coagulation studies (PT/INR, aPTT, platelets), serum creatinine
      • Baseline chest X-ray and arterial blood gas (ABG) in patients with significant pulmonary disease
      • Remove dentures, hearing aids, and jewelry before procedure
      • Arrange for responsible adult to drive patient home due to conscious sedation or local anesthesia effects
      • Pre-medication with topical lidocaine throat spray 30 minutes before procedure
      • IV access established for sedation administration
      • Oxygen saturation monitoring and cardiac monitoring equipment prepared
      • Post-procedure NPO (nothing by mouth) for 2 hours following throat anesthesia resolution
      • Post-procedure monitoring for bleeding, fever, dyspnea, or chest pain for 2 hours minimum

How our test process works!

customers
customers